Peer-reviewed veterinary case report
Cat with rare lymphoma lived 982 days after chemo and immune therapy
By Shimon Furusato et al.·Published in Open Veterinary Journal·2022·Shinagawa WAF Animal Hospital, Tokyo, Japan, LY·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Long-term survival of a feline with non-T/B large granular lymphocyte lymphoma treated with chemotherapy and activated lymphocyte therapy
- Species:
- cat
Plain-English summary
A 7-year-old male domestic cat was brought to the vet with gastrointestinal issues and an abdominal mass. After a biopsy confirmed he had a type of cancer called large granular lymphocyte lymphoma, he was treated with a combination of chemotherapy drugs and an additional therapy using activated lymphocytes. Remarkably, the cat responded well to the treatments and lived for nearly three years after his diagnosis, experiencing only a few side effects. This case suggests that combining these therapies can be a safe and effective option for cats with this serious condition.
People also search for: cat abdominal mass treatment · feline lymphoma chemotherapy · activated lymphocyte therapy for cats
Abstract
Background: Feline large granular lymphocyte lymphoma (LGLL) is a grave prognosis. However, the effectiveness of concurrent treatment with chemotherapy and activated lymphocyte therapy for feline LGLL has not been evaluated. Case Description: A 7-year-old, castrated male, domestic cat presented with gastrointestinal symptoms and an abdominal mass. A Tru-Cut biopsy of the mass revealed LGLL. The cat responded well to chemotherapy regimens of cyclophosphamide, vincristine, prednisolone, and L-asparaginase. Further, activated lymphocyte therapy was added as an adjuvant treatment. The cat survived 982 days from the first presentation and experienced few adverse events. Necropsy was performed and immunohistochemistry revealed that the neoplastic lymphocytes were CD3−/CD20− cells. The final diagnosis was non-T/B LGLL. Conclusion: Minimal physical burden and a good initial response to chemotherapy might have contributed to long-term survival in the present case. Moreover, activated lymphocyte therapy could be performed safely and may be a feasible treatment for feline non-T/B LGLL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.5455/OVJ.2022.v12.i3.2